UY30302A1 - Formulaciones de pepticuerpos terapeuticos liofilizados - Google Patents

Formulaciones de pepticuerpos terapeuticos liofilizados

Info

Publication number
UY30302A1
UY30302A1 UY30302A UY30302A UY30302A1 UY 30302 A1 UY30302 A1 UY 30302A1 UY 30302 A UY30302 A UY 30302A UY 30302 A UY30302 A UY 30302A UY 30302 A1 UY30302 A1 UY 30302A1
Authority
UY
Uruguay
Prior art keywords
formulations
liofilized
therapeutic
therapeutic peptibodies
peptibodies
Prior art date
Application number
UY30302A
Other languages
English (en)
Spanish (es)
Inventor
Dingjiang Liu
Ramil F Latypov
Gayathri Ratnaswamy
Richard L Remmele Jr
William J Callahan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38625630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30302(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY30302A1 publication Critical patent/UY30302A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
UY30302A 2006-04-21 2007-04-20 Formulaciones de pepticuerpos terapeuticos liofilizados UY30302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79399706P 2006-04-21 2006-04-21
US11/788,697 US9283260B2 (en) 2006-04-21 2007-04-19 Lyophilized therapeutic peptibody formulations

Publications (1)

Publication Number Publication Date
UY30302A1 true UY30302A1 (es) 2007-10-31

Family

ID=38625630

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30302A UY30302A1 (es) 2006-04-21 2007-04-20 Formulaciones de pepticuerpos terapeuticos liofilizados

Country Status (38)

Country Link
US (2) US9283260B2 (enExample)
EP (6) EP2594286A1 (enExample)
JP (6) JP5432705B2 (enExample)
KR (2) KR101227278B1 (enExample)
CN (2) CN107789325A (enExample)
AR (1) AR060617A1 (enExample)
AU (1) AU2007240656A1 (enExample)
BR (1) BRPI0710508B8 (enExample)
CA (1) CA2649292C (enExample)
CR (3) CR20170130A (enExample)
CY (1) CY1118038T1 (enExample)
DK (1) DK2018183T3 (enExample)
EA (2) EA022424B1 (enExample)
ES (1) ES2599318T3 (enExample)
GE (1) GEP20156253B (enExample)
HR (1) HRP20161653T1 (enExample)
HU (1) HUE032144T2 (enExample)
IL (3) IL194653A (enExample)
JO (1) JO3324B1 (enExample)
LT (1) LT2018183T (enExample)
MA (1) MA30474B1 (enExample)
MX (1) MX2008013393A (enExample)
MY (1) MY162816A (enExample)
NO (1) NO344947B1 (enExample)
NZ (1) NZ596367A (enExample)
PE (1) PE20081196A1 (enExample)
PH (1) PH12014502880A1 (enExample)
PL (1) PL2018183T3 (enExample)
PT (1) PT2018183T (enExample)
RS (1) RS55428B1 (enExample)
SG (2) SG182887A1 (enExample)
SI (1) SI2018183T1 (enExample)
TN (1) TNSN08391A1 (enExample)
TW (1) TWI352598B (enExample)
UA (2) UA99815C2 (enExample)
UY (1) UY30302A1 (enExample)
WO (1) WO2007124090A2 (enExample)
ZA (1) ZA200808485B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279649T3 (es) 1998-10-23 2007-08-16 Amgen Inc. Compuestos trombopoyeticos.
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CZ307715B6 (cs) 1999-02-22 2019-03-06 University Of Connecticut Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
EE200100651A (et) 1999-06-01 2003-02-17 Biogen, Inc. VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks
NZ529494A (en) 2001-04-13 2005-08-26 Biogen Idec Inc Antibodies to VLA-1
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
KR20110007614A (ko) * 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
KR101752508B1 (ko) * 2008-11-07 2017-06-29 백스터 인터내셔널 인코포레이티드 제8 인자 제형
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
AU2011207916B2 (en) * 2010-01-19 2014-01-23 Hanmi Science Co., Ltd. Liquid formulations for long-acting erythropoietin conjugate
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2646051A4 (en) 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
SG190419A1 (en) 2010-12-02 2013-06-28 Oncolytics Biotech Inc Lyophilized viral formulations
JP5759211B2 (ja) * 2011-03-11 2015-08-05 三洋化成工業株式会社 凍結乾燥方法
US9151761B2 (en) 2011-06-29 2015-10-06 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
DE102011055889B4 (de) * 2011-11-30 2013-08-01 Otc Gmbh Verfahren zur Herstellung eines Protein-Hydrolysates
CN102586217A (zh) * 2011-12-16 2012-07-18 深圳市海普瑞药业股份有限公司 肝素黄杆菌肝素酶ⅰ、ⅱ、ⅲ的冻干保存方法
RU2482128C1 (ru) * 2011-12-28 2013-05-20 Замертон Холдингс Лимитед Пептиды, обладающие цитопротекторной активностью
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
EP2644186A1 (en) * 2012-03-26 2013-10-02 OTC GmbH Hair conditioning composition for permanent and semi-permanent hair coloration applications
EP2863898A4 (en) * 2012-06-25 2016-04-27 Emergent Product Dev Gaithersburg Inc STABLE TEMPERATURE VACCINE FORMULATIONS
CN104507969A (zh) 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 抗siglec-15抗体
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
KR20150140294A (ko) * 2013-03-15 2015-12-15 암젠 인코퍼레이티드 사람 대상에서 미오스타틴 길항작용
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
WO2015035405A1 (en) * 2013-09-09 2015-03-12 Pinta Biotherapeutics, Inc. Myostatin antagonist for treatment of pew in esrd patients
MX368943B (es) * 2013-11-07 2019-10-22 Dr August Wolff Gmbh & Co Kg Arzneimittel Formulaciones de tripeptido liofilizado estables en almacenamiento.
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR102429859B1 (ko) * 2013-12-06 2022-08-04 더 브로드 인스티튜트, 인코퍼레이티드 신생물 백신을 위한 제형
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3086780A4 (en) 2013-12-27 2017-08-09 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
EP3125923B1 (en) * 2014-03-29 2024-10-16 Intas Pharmaceuticals Limited Lyophilized pharmaceutical composition of fc-peptide fusion protein
ES2784500T3 (es) * 2014-05-28 2020-09-28 Nono Inc Sal de cloruro de Tat-NR2B9c
EA201692568A1 (ru) * 2014-06-13 2017-05-31 Санта Мария Биотерапевтикс, Инк. Составы с полипептидами-рецепторами и связанные с ними способы
EA036091B1 (ru) * 2014-08-20 2020-09-25 Портола Фармасьютикалз, Инк. ВОДНЫЕ СОСТАВЫ АНТИДОТОВ ФАКТОРА Xa (fXa) ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ УМЕНЬШЕНИЯ КРОВОТЕЧЕНИЯ И ИХ ПРИМЕНЕНИЕ
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US10857229B2 (en) 2015-04-30 2020-12-08 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3400019B1 (en) 2016-01-08 2022-09-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
KR20180100624A (ko) 2016-01-08 2018-09-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 증가된 nep 안정성을 갖는 제어 방출성 cnp 작용제
CA3007982C (en) 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
JP6992262B2 (ja) * 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
EP3454903A4 (en) * 2016-05-13 2020-08-19 Askgene Pharma, Inc. NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP2017155046A (ja) * 2017-04-05 2017-09-07 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
MX2020002896A (es) 2017-09-15 2020-07-22 Amgen Inc Proceso para formulacion farmaceutica liofilizada de una proteina terapeutica.
WO2019055902A1 (en) * 2017-09-18 2019-03-21 Amgen Inc. FUSION PROTEIN FORMULATIONS VEGFR-FC
JP7692699B2 (ja) * 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
CN108159413B (zh) * 2018-01-10 2021-07-06 杭州洪桥中科基因技术有限公司 一种动物用冻干活疫苗及其制备方法
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
DK3793588T3 (da) 2018-05-18 2025-06-16 Bioverativ Therapeutics Inc Fremgangsmåder til behandling af hæmofili a
CN112533639A (zh) * 2018-07-31 2021-03-19 安进公司 掩蔽的抗体的药物配制品
SG11202107446QA (en) 2019-02-11 2021-08-30 Ascendis Pharma Growth Disorders As Dry pharmaceutical formulations of cnp conjugates
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
BR112021019612A2 (pt) * 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
DK3744319T3 (da) 2019-05-28 2023-01-16 Ilkogen Ilac Sanayi Ve Ticaret A S Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf
JP2019178154A (ja) * 2019-06-18 2019-10-17 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
EP4069847A4 (en) * 2019-12-02 2023-11-15 Onspira Therapeutics, Inc. Treatment of lower airways disorders
WO2021113440A2 (en) * 2019-12-03 2021-06-10 China Medical University Oligopeptide, testing kit thereof, medical composition thereof and use of medical composition
EP4074337B1 (en) 2019-12-10 2025-05-07 RemeGen Co., Ltd. Pharmaceutical taci-fc fusion protein formulation
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
CN120904344A (zh) * 2021-03-31 2025-11-07 杭州嘉因生物科技有限公司 靶向vegf和血管生成素的融合分子及其用途
JP2024542784A (ja) 2021-12-01 2024-11-15 ユーシービー バイオファーマ エスアールエル Ｆａｂ－ＰＥＧを含む製剤
US20240076597A1 (en) * 2022-09-02 2024-03-07 Terumo Bct, Inc. Methods for cell expansion, differentiation, and/or harvesting of natural killer cells using hollow-fiber membranes
WO2024133908A1 (en) * 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Stable pharmaceutical compositions comprising romiplostim
WO2024263570A1 (en) * 2023-06-23 2024-12-26 The Regents Of The University Of Michigan Nanoparticle compositions associated with peptides
CN118126120B (zh) * 2023-09-14 2024-12-06 海南大学 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE3244265A1 (de) 1982-11-30 1984-05-30 Cassella Ag, 6000 Frankfurt Weichmacheremulsion, verfahren zu ihrer herstellung und ihre anwendung
US4503235A (en) 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5844929A (en) * 1994-02-24 1998-12-01 British Telecommunications Public Limited Company Optical device with composite passive and tapered active waveguide regions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
IL116026A (en) 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5888763A (en) 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
DK2275119T3 (da) 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5714577A (en) 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP4088344B2 (ja) 1996-03-28 2008-05-21 カイロン コーポレイション ウロキナーゼレセプターのペプチドリガンド
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
FR2748028B1 (fr) 1996-04-30 1998-08-14 Lab Francais Du Fractionnement Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant
DE69737229T2 (de) 1996-06-07 2008-01-31 Takeda Pharmaceutical Co. Ltd. Peptid mit cortistatin- oder somatostatin-aktivität, verfahren zu dessen herstellung und dessen verwendungen
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
JP2001501600A (ja) 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
WO1998014476A1 (en) 1996-10-04 1998-04-09 Amgen Inc. Pharmaceutical compositions containing an mpl ligand
CA2267139A1 (en) 1996-10-08 1998-04-16 Ton Logtenberg Methods and means for selecting peptides and proteins having specific affinity for a target
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
EP0975754B2 (en) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE235513T1 (de) 1997-11-07 2003-04-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen
AU2481399A (en) 1998-01-29 1999-08-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variant peptide ligands that selectively induce apoptosis
ATE279430T1 (de) 1998-03-05 2004-10-15 Chiron Corp Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
US6235872B1 (en) 1998-03-12 2001-05-22 The Burnham Institute Proapoptotic peptides dependence polypeptides and methods of use
JP4361684B2 (ja) 1998-03-20 2009-11-11 中外製薬株式会社 エリトロポエチン受容体のためのペプチドリガンド
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
WO1999051254A1 (en) 1998-04-06 1999-10-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
DK1075282T3 (da) 1998-04-28 2005-10-10 Applied Research Systems PEG-LHRH-analog-konjugater
EP0972780A1 (en) 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
SK286554B6 (sk) 1998-05-22 2008-12-05 Abbott Laboratories Peptidické antiangiogénne liečivá, farmaceutický prostriedok s ich obsahom a ich použitie
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000001402A1 (en) 1998-07-02 2000-01-13 Envision Biomedical Consulting Antiproliferative and antiviral proteins and peptides
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
AU5300299A (en) 1998-08-21 2000-03-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
ES2265693T3 (es) 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2279649T3 (es) 1998-10-23 2007-08-16 Amgen Inc. Compuestos trombopoyeticos.
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AU2880400A (en) 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CA2407956A1 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
US6853809B2 (en) 2001-01-30 2005-02-08 Koninklijke Philips Electronics N.V. Camera system for providing instant switching between wide angle and full resolution views of a subject
NZ529267A (en) 2001-05-11 2006-05-26 Amgen Inc Peptides and related molecules that bind to tall-1
RU2180233C1 (ru) 2001-06-26 2002-03-10 Общество с ограниченной ответственностью "Протеиновый контур" Способ получения жидких лекарственных форм рекомбинантных белков
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040247588A1 (en) 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
RS52815B (sr) 2002-12-20 2013-10-31 Amgen Inc. Vezivna sredstva koja inhibiraju miostatin
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
BRPI0516011A (pt) 2004-09-24 2008-08-19 Amgen Inc moléculas fc modificadas
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP3035305B1 (en) 2014-12-18 2016-11-16 Axis AB Enclosure and arrangement for recess mounting of a camera or camera head

Also Published As

Publication number Publication date
KR101236042B1 (ko) 2013-02-21
HUE032144T2 (en) 2017-08-28
US10166189B2 (en) 2019-01-01
MA30474B1 (fr) 2009-06-01
US20090258017A1 (en) 2009-10-15
IL194653A0 (en) 2011-08-01
PT2018183T (pt) 2016-12-02
US20160143852A1 (en) 2016-05-26
EA201270625A1 (ru) 2012-12-28
JO3324B1 (ar) 2019-03-13
GEP20156253B (en) 2015-03-10
AU2007240656A1 (en) 2007-11-01
HRP20161653T1 (hr) 2017-01-13
JP2022166219A (ja) 2022-11-01
IL248156B (en) 2018-07-31
CN107789325A (zh) 2018-03-13
JP5873854B2 (ja) 2016-03-01
SG10201501296SA (en) 2015-04-29
MY162816A (en) 2017-07-31
CA2649292C (en) 2017-01-17
CR20170130A (es) 2017-06-15
KR101227278B1 (ko) 2013-01-28
CA2649292A1 (en) 2007-11-01
JP2014040441A (ja) 2014-03-06
WO2007124090A2 (en) 2007-11-01
JP6356106B2 (ja) 2018-07-11
JP2016065060A (ja) 2016-04-28
EP2594287A1 (en) 2013-05-22
LT2018183T (lt) 2016-11-25
MX2008013393A (es) 2009-03-06
JP2021006525A (ja) 2021-01-21
ES2599318T3 (es) 2017-02-01
PH12014502880A1 (en) 2016-01-18
NO20084893L (no) 2009-01-20
JP5432705B2 (ja) 2014-03-05
TNSN08391A1 (en) 2010-04-14
UA99815C2 (ru) 2012-10-10
KR20120114384A (ko) 2012-10-16
JP2018150380A (ja) 2018-09-27
BRPI0710508B8 (pt) 2021-05-25
NO344947B1 (no) 2020-07-27
CY1118038T1 (el) 2017-05-17
NZ596367A (en) 2013-09-27
EA017085B1 (ru) 2012-09-28
PE20081196A1 (es) 2008-09-04
TWI352598B (en) 2011-11-21
EA200802170A1 (ru) 2009-06-30
EP2594285A1 (en) 2013-05-22
PL2018183T3 (pl) 2017-04-28
EA022424B1 (ru) 2015-12-30
CR10442A (es) 2009-02-19
EP2594288A1 (en) 2013-05-22
JP6787953B2 (ja) 2020-11-18
EP2594285B1 (en) 2016-08-10
US9283260B2 (en) 2016-03-15
SI2018183T1 (sl) 2017-01-31
TW200744624A (en) 2007-12-16
IL194653A (en) 2016-10-31
KR20090005204A (ko) 2009-01-12
EP2018183B1 (en) 2016-09-07
WO2007124090A3 (en) 2008-12-11
AR060617A1 (es) 2008-07-02
RS55428B1 (sr) 2017-04-28
JP2009534392A (ja) 2009-09-24
IL224966A (en) 2017-10-31
EP2018183A2 (en) 2009-01-28
EP2594284A1 (en) 2013-05-22
DK2018183T3 (en) 2016-11-28
BRPI0710508A2 (pt) 2012-10-30
CN101484185A (zh) 2009-07-15
UA116080C2 (uk) 2018-02-12
SG182887A1 (en) 2012-08-30
BRPI0710508B1 (pt) 2018-10-23
EP2594286A1 (en) 2013-05-22
ZA200808485B (en) 2009-08-26
CR20140274A (es) 2014-07-18

Similar Documents

Publication Publication Date Title
UY30302A1 (es) Formulaciones de pepticuerpos terapeuticos liofilizados
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
CR11106A (es) Inhibidores de cinasa p710 s6
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
CR20110110A (es) Composicion farmaceutica
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
UY30495A1 (es) Formulaciones de modificador de respuesta inmune
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
AR059964A1 (es) Metodos para reducir la aglomeracion de proteina
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
HN2008000278A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica
CR20120476A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
CR10505A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
AR058691A1 (es) Sonda microquirurgica
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
PA8667201A1 (es) Nuevos compuestos farmaceuticos
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
PA8624601A1 (es) Macrolidos y metodos para producir los mismos
SV2009003287A (es) Agentes para combatir parasitos en animales
PA8846401A1 (es) Sinergismo antibiótico
CR10490A (es) Vacuna combinada estreptococica
ATE552832T1 (de) Antidepressivum-propharmaka

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20190423